title: Neurolymphomatosis--diagnosis and assessment of treatment response by FDG PET-CT.
abstract: Neurolymphomatosis (NL) is lymphomatous infiltration of peripheral nerves, and is an uncommon manifestation of non-Hodgkin's lymphoma (NHL). Although nerve biopsy is the main method for histological diagnosis, a blind nerve biopsy may not be diagnostic. While CT and MRI have been used to detect NL, recent reports demonstrated the benefit of integrated positron emission tomography (PET) using F18-2-fluoro-2-deoxy-D-glucose (FDG) combined with computed tomography (CT). We described the utility of FDG PET-CT in this uncommon subgroup of NHL where it can assist in establishing the diagnosis, the potential to guide sites for biopsy and in the assessment of response to therapy.
authors.affiliation: Department of Nuclear Medicine and PET, Liverpool Hospital, Liverpool, NSW 2170, Australia. michael.lin@swsahs.nsw.gov.au
authors.forename: M
authors.initials: M
authors.lastname: Lin
authors.forename: J
authors.initials: J
authors.lastname: Kilanowska
authors.forename: J
authors.initials: J
authors.lastname: Taper
authors.forename: J
authors.initials: J
authors.lastname: Chu
mesh_terms: D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D016393:Lymphoma, B-Cell / Q000150:complications*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000150:complications*; D008875:Middle Aged; D010524:Peripheral Nervous System Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy; D049268:Positron-Emission Tomography; D014057:Tomography, X-Ray Computed
chemical_list: D019788:Fluorodeoxyglucose F18